ABEO - CIK 0000318306
ABEONA THERAPEUTICS INC. trades as ABEO. In its fiscal 2025 annual report the company posted revenue of $5.82M, up 66.3% from the prior year and net income of -$71.18M. This page tracks ABEONA THERAPEUTICS INC. through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 11 fiscal years ABEONA THERAPEUTICS INC.'s revenue grew from $925.00K to $5.82M, a compound annual growth rate of 18.2%. Net profit margin expanded from -2460.4% to -1223.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-15 |
| Insider trade | 4 | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
The largest companies sharing ABEONA THERAPEUTICS INC.'s SEC industry classification (pharmaceutical preparations).
ABEONA THERAPEUTICS INC. reported revenue of $5.82M for fiscal year 2025, an increase of 66.3% year over year.
In its latest fiscal year ABEONA THERAPEUTICS INC. reported a net loss of $71.18M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.